(Epi)genome replication - Publications

• Fajri N, Petryk N^#. Monitoring and quantifying replication fork dynamics with high-throughput methods. Commun Biol. 2024 Jun 14;7(1):729. doi: 10.1038/s42003-024-06412-1.
• Wu X*, Liu Y*, Daubenton-Carafa Y ; Thermes C ; Chen CL#, Hyrien O#, Petryk N#. Genome-wide measurement of DNA replication fork directionality and quantification of DNA replication initiation and termination with Okazaki fragment sequencing. Nature protocols. 2023 Apr;18(4):1260-1295. doi: 10.1038/s41596-022-00793-5.

(Epi)genome replication: research topics

This team belongs to the UMR 9019 Genome Integrity and Cancers.

Our goal is to understand how cells copy both their DNA and epigenome during division. Disruptions in this process can lead to changes in cell identity and contribute to cancer.

Tumour immunology and anti-cancer immunotherapy

The team belongs to the UMR 1015 - Tumour immunology and anti-cancer immunotherapy

The unit "Tumour immunology and anti-cancer immunotherapy" consists of four groups:

Organization of the Biological Resource Center

The Gustave Roussy Biobank is structured into two modules:

Biological Resource Center presentation

The Gustave Roussy Biobank’s mission is to contribute to cancer research by providing research teams with high-quality biological resources.

It has been created in 2001 to centralize the management of biological resources from healthcare and for research purposes, thereby ensuring optimal technical support and traceability of samples and their associated data.

In 2011, the “fluid” module from clinical trials has been integrated into the CRB, expanding the department's scope of activity.

Gustave Roussy est présent au plus grand congrès annuel en cancérologie organisé par l’American Society of Clinical Oncology (ASCO) du 31mai au 4 juin 2024. Ce temps fort rend compte des dernières innovations et résultats de recherche clinique en cancérologie.

Gustave Roussy au congrès de l’ASCO 2024 : une édition particulièrement riche

► Lire l'actualité

Molecular Radiotherapy and Therapeutic Innovation

This team belongs to the UMR 1030 - Molecular radiotherapy and therapeutic innovations

Our team is composed of 2 groups:

• The Cell death, Immunity and Therapeutic Innovation group led by Dr. Jean-Luc PERFETTINI
• The Radiotherapy, ImmunoRadAI group led by Pr. Eric DEUTSCH

The REMISSION program was granted by the 6^th call for projects of the Hospital-University Research (RHU) endeavor of the France 2030 government investment plan. It proposes to use fresh tissues (blood and tumor) as a source of biomarkers to adapt new immunotherapy strategies to the biology of patients and their cancer. This program aligns with Gustave Roussy's objectives to personalize treatments for cancer patients.

Immunothérapie : les vaccins thérapeutiques

Lors de la dernière décennie, la révolution entraînée par l’immunothérapie en cancérologie a permis des avancées majeures au bénéfice du patient. Les chercheurs ne visent plus uniquement à s’attaquer directement aux cellules cancéreuses, comme le font la chimiothérapie ou la radiothérapie, mais à renforcer le système immunitaire du malade pour qu’il les élimine lui-même.